Zobrazeno 1 - 10
of 334
pro vyhledávání: '"Eric, Lawitz"'
Autor:
Philip N. Newsome, Arun J. Sanyal, Guy Neff, Jörn M. Schattenberg, Vlad Ratziu, Judith Ertle, Jasmin Link, Alison Mackie, Corinna Schoelch, Eric Lawitz, BI 1467335 NASH Phase IIa trial team
Publikováno v:
Nature Communications, Vol 14, Iss 1, Pp 1-11 (2023)
Abstract Non-alcoholic steatohepatitis (NASH) is a progressive, inflammatory liver disease with no approved pharmacological treatment. This Phase IIa, double-blind, placebo-controlled, multicentre trial (ClinicalTrials.gov: NCT03166735) investigated
Externí odkaz:
https://doaj.org/article/f8f75d8f1dd9428aae4a8f04531f0a04
Autor:
Steven Flamm, Eric Lawitz, Brian Borg, Michael Charlton, Charles Landis, K. Rajender Reddy, Mitchell Shiffman, Angel Alsina, Charissa Chang, Natarajan Ravendhran, Candido Hernandez, Christophe Hézode, Stacey Scherbakovsky, Renee-Claude Mercier, Didier Samuel
Publikováno v:
Viruses, Vol 15, Iss 10, p 2026 (2023)
A fixed-dose combination of sofosbuvir/velpatasvir (SOF/VEL) plus weight-based ribavirin (RBV) for 12 weeks is recommended for the treatment of patients with hepatitis C virus (HCV)-associated decompensated cirrhosis. However, large global studies, w
Externí odkaz:
https://doaj.org/article/620ad64d8bc644198848a98512cd84c1
Autor:
Rohit Loomba, Manal F Abdelmalek, Matthew J Armstrong, Maximilian Jara, Mette Skalshøi Kjær, Niels Krarup, Eric Lawitz, Vlad Ratziu, Arun J Sanyal, Jörn M Schattenberg, Philip N Newsome
Publikováno v:
The Lancet Gastroenterology & Hepatology. 8:511-522
Autor:
Eric Lawitz, Edward Gane, Eric Cohen, John Vierling, Kosh Agarwal, Tarek Hassanein, Parvez S. Mantry, Paul J. Pockros, Michael Bennett, Nyingi Kemmer, Giuseppe Morelli, Jiuhong Zha, Deli Wang, Nancy S. Shulman, Daniel E. Cohen, K. Rajender Reddy
Publikováno v:
Kidney International Reports, Vol 4, Iss 2, Pp 257-266 (2019)
Introduction: Hepatitis C virus (HCV) infection is common in patients with end-stage renal disease. We investigated the safety and efficacy of ombitasvir (OBV)/paritaprevir (PTV)/ritonavir (r) ± dasabuvir (DSV) ± ribavirin (RBV) in 2 phase 3, open-
Externí odkaz:
https://doaj.org/article/4057d33cf90442e09159e38451382b6a
Autor:
Eric Lawitz, Fred Poordad, Julio A. Gutierrez, Maria Beumont, Greet Beets, Ann Vandevoorde, Pieter Van Remoortere, Donghan Luo, Leen Vijgen, Veerle Van Eygen, Mohamed Gamil
Publikováno v:
Health Science Reports, Vol 3, Iss 2, Pp n/a-n/a (2020)
Abstract Background and aims Direct‐acting antiviral agents (DAAs) for hepatitis C virus (HCV) infection have resulted in high rates of sustained virologic response (SVR) following 8 to 24 weeks of treatment. However, difficult‐to‐cure/cirrhoti
Externí odkaz:
https://doaj.org/article/61e6a0119abd4699b62cba409899ce21
Publikováno v:
Hepatology Communications, Vol 2, Iss 7, Pp 778-785 (2018)
Nonalcoholic fatty liver disease (NAFLD) is considered the hepatic manifestation of insulin resistance, which is the hallmark of type 2 diabetes (T2D). NAFLD is a known risk factor for developing T2D and has a very high prevalence in those with exist
Externí odkaz:
https://doaj.org/article/d4611e839e434658bf0848f4128246b0
Autor:
Fabien Zoulim, Christophe Moreno, Samuel S. Lee, Peter Buggisch, Andrzej Horban, Eric Lawitz, Chris Corbett, Oliver Lenz, Bart Fevery, Thierry Verbinnen, Umesh Shukla, Wolfgang Jessner
Publikováno v:
Virology Journal, Vol 15, Iss 1, Pp 1-11 (2018)
Abstract Background Simeprevir is approved with pegylated interferon and ribavirin (PR) for chronic hepatitis C virus (HCV) genotype (GT) 1 and GT4 infection in the USA and the European Union. Methods This 3-year follow-up study assessed the durabili
Externí odkaz:
https://doaj.org/article/12546fb5318c449181ab2d29342193b1
Autor:
Eric Lawitz, Manuel Romero-Gómez, Quentin M. Anstee, Stephen A. Harrison, Catherine Jia, Zobair M. Younossi, Chuhan Chung, Zachary Goodman, Robert P. Myers, Ryan S Huss, Michael Trauner, Vincent Wai-Sun Wong, Andrew J. Muir, Takeshi Okanoue, Jaime Bosch, D. Ding, Nezam H. Afdhal, Manal F. Abdelmalek, Ling Han, Arun J. Sanyal
Publikováno v:
Sanyal, Arun J; Anstee, Quentin M; Trauner, Michael; Lawitz, Eric J; Abdelmalek, Manal F; Ding, Dora; Han, Ling; Jia, Catherine; Huss, Ryan S; Chung, Chuhan; Wong, Vincent Wai-Sun; Okanoue, Takeshi; Romero-Gomez, Manuel; Muir, Andrew J; Afdhal, Nezam H; Bosch, Jaime; Goodman, Zachary; Harrison, Stephen A; Younossi, Zobair M and Myers, Robert P (2022). Cirrhosis Regression is Associated with Improved Clinical Outcomes in Patients with Nonalcoholic Steatohepatitis. Hepatology, 75(5), pp. 1235-1246. Wiley 10.1002/hep.32204
[Background and Aims] Surrogate endpoints that predict complications are necessary for assessment and approval of NASH therapies. We assessed associations between histologic and noninvasive tests (NITs) of fibrosis with liver‐related complications
Autor:
Manal F. Abdelmalek, Ayako Suzuki, Willian Sanchez, Eric Lawitz, Claudia Filozof, Hyungjin Cho, Eunhye Baek, JaeDuk Choi, Seungjae Baek
Publikováno v:
Contemporary Clinical Trials. 130:107176
Autor:
Shuyan Du, Diane E. Shevell, Warner Chen, Edgar D. Charles, Uma Kavita, Angie Coste, Fred Poordad, Zachary Goodman, Eric Lawitz, Mette Juul Nielsen, Giridhar S. Tirucherai, Morten A. Karsdal
Publikováno v:
Hepatology. 75:912-923
Background & aims Hepatic fibrosis secondary to HCV infection can lead to cirrhosis and hepatic decompensation. Sustained virologic response (SVR) is possible with direct-acting antiviral drug regimens; however, patients with advanced fibrosis have a